NCT07218341 2026-02-10A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaEli Lilly and CompanyPhase 4 Not yet recruiting150 enrolled
NCT02970318 2026-02-06A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLLAcerta Pharma BVPhase 3 Active not recruiting310 enrolled 18 charts 1 FDA
NCT07139873 2025-11-18A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)Dizal PharmaceuticalsPhase 3 Recruiting250 enrolled
NCT02457598 2025-06-17Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell MalignanciesGilead SciencesPhase 1 Terminated203 enrolled 43 charts
NCT04666038 2025-04-20BRUIN CLL-321Eli Lilly and CompanyPhase 3 Active not recruiting238 enrolled 17 charts 1 FDA